Clinical trials: Genome
Cancer, NGS
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.
- Conditions
- Cancer, NGS, Tumor, RARE DISEASE
- Trial name
- SONCO (NCT07147465)
- Where
- 3 sites in France
- Volunteers
- 3,149 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
BRCA1 Mutation, Breast Cancer
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of recombinant human chorionic gonadotropin may prevent breast cancer in premenopausal women with BRCA1 mutations.
- Trial name
- NCT00700778
- Testing
- recombinant human chorionic gonadotropin, microarray analysis, immunohistochemistry staining method
- Where
- 3 sites in United States, Austria
- Volunteers
- 2 people
- Sponsor
- Fox Chase Cancer Center
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Coronary Heart Disease, Type 2 Diabetes
Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys Study
P5.fi study - P4 together with a fifth 'P' and '.fi' for population health Finally Implemented in Finland - studies the value of returning genetic and metabolomic risk information in two diseases (coronary heart disease and type…
- Conditions
- Coronary Heart Disease, Type 2 Diabetes, Deep Vein Thrombosis
- Trial name
- P5 (NCT03650127)
- Where
- Finland
- Volunteers
- 3,449 people, healthy volunteers welcome
- Sponsor
- Markus Perola
Biliary Tract Carcinoma
Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma
Chromosomal instability (CIN) refers to ongoing chromosome segregation errors throughout consecutive cell divisions. CIN is a hallmark of human cancer, and it is associated with poor prognosis, metastasis, and therapeutic…
- Trial name
- NCT05845554
- Testing
- The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
Non-small Cell Lung Carcinoma, Urothelial Carcinoma
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
With the increased availability of next-generation sequencing, oncologists are starting to incorporate genomic profiling into routine care of cancer patients.
- Conditions
- Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma
- Trial name
- NCT02795156
- Testing
- Afatinib, Regorafenib, Cabozantinib
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Autoimmune Encephalitis
GWAS in NMDAR Encephalitis
Autoimmune encephalitis are characterized by the subacute development of memory deficits, altered mental status, and psychiatric symptoms, generally in association with anti-neuronal antibodies.
- Trial name
- NCT05225883
- Testing
- GWAS
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
Malignancy
BostonGene-Integrated Genomic Registry (BIGR)
The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to…
- Trial name
- NCT04991922
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- BostonGene
Unruptured Cerebral Aneurysm
Identification of Genetic Polymorphisms Related to Propofol Requirement and Recovery Through Genome-wide Association Study (GWAS) in Total Intravenous Anesthesia for Clipping of Unruptured Cerebral Aneurysm in Korean Population
In neurosurgical anesthesia, propofol based total intravenous anesthesia (TIVA) is frequently used due to brain relaxation and less effect on electrophysiologic monitoring.
- Trial name
- NCT03087383
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Yonsei University
Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5
Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma
Background: Colorectal neuroendocrine carcinomas (CRNECs) are highly aggressive tumours with poor prognosis and low incidence. To date, the genomic landscape and molecular pathway alterations have not been elucidated.
- Trial name
- NCT05714722
- Volunteers
- 60 people
- Sponsor
- Zhejiang University
Sequence Analysis
Analysis of Tumor Mutations and Tumor Microenvironment Using Archival Paraffin-embedded Tumor Specimens
Genomic alterations have long been recognized as an important factor in tumor formation and drive tumor cell growth. However, the degree of genomic mutation (tumor mutation load, TMB) varies widely between tumors.
- Trial name
- NCT03719222
- Testing
- non intervention
- Where
- Taiwan
- Volunteers
- 600 people
- Sponsor
- ACT Genomics
Non Muscle Invasive Bladder Cancer
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
This study is a prospective, randomized, multicenter clinical trial aiming to enroll 428 patients with non-muscle-invasive bladder cancer (NMIBC) from the Department of Urology at Jiangsu Provincial People's Hospital and its…
- Trial name
- NCT07036731
- Testing
- Urine biomarker -Guided without reTURBT
- Where
- China
- Volunteers
- 428 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Recurrent Prostate Cancer
FACBC for Recurrent Prostate Cancer
The investigators will perform a study with 25 patients in whom the investigators have a strong suspicion of prostate cancer that has returned to the body after having an initial treatment.
- Trial name
- NCT01808222
- Testing
- FACBC
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- David M. Schuster, MD
Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia
This pilot research trial studies biomarkers in bone marrow samples from pediatric patients with high risk acute myeloid leukemia.
- Conditions
- Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
- Trial name
- NCT01076569
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Children's Oncology Group
Malignant Solid Tumor
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
This trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts…
- Trial name
- MegaMOST (NCT04116541)
- Testing
- HDM201, Ribociclib, Cabozantinib
- Where
- 13 sites in France
- Volunteers
- 455 people
- Sponsor
- Centre Leon Berard
Acute Myeloid Leukemia
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is…
- Trial name
- NCT02756962
- Testing
- Cytarabine, Allogeneic stem cell transplant, Bone marrow aspiration
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- Washington University School of Medicine
Microgravity, Neuroplasticity
Neuroimage Genome Study of Neuroplasticity Associated With Microgravity
This clinical trial investigates the neuroplasticity and cognitive status changes of the human brain in microgravity. To explore the relationship between cognitive status changes and brain functional activities, gray matter and…
- Conditions
- Microgravity, Neuroplasticity, MRI, Repeatable Battery for the Assessment of Neuropsychological Status
- Trial name
- NCT06350422
- Testing
- Head-Down tilt Bed Rest test
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Breast Cancer, Lung Cancer
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- CAPTIV-8 (NCT04273061)
- Testing
- Atezolizumab
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Oral Cancer, Oropharynx Cancer
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
There is no consensus on the indication of postoperative radiotherapy for early stages oral and oropharyngeal squamous cell carcinoma with complete pathological resection and no neck node metastasis, but most of the institutions…
- Trial name
- NCT00232960
- Testing
- Radiotherapy 50 Gy
- Where
- 4 sites in France
- Volunteers
- 310 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Advanced or Metastatic NSCLC
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and…
- Trial name
- LOTOS (NCT05941897)
- Testing
- Ceralasertib, Durvalumab
- Where
- 8 sites in Russia
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.